Skip banner
HomeSourcesHow Do I?OverviewHelp
Return To Search FormFOCUS
Search Terms: patent, extension, drug

Document ListExpanded ListKWICFULL format currently displayed

Previous Document Document 51 of 195. Next Document

Copyright 2000 P.G. Publishing Co.  
Pittsburgh Post-Gazette

August 17, 2000, Thursday, SOONER EDITION

SECTION: BUSINESS, Pg. F-1, NEWS BRIEFS

LENGTH: 595 words

HEADLINE: NO HEADLINE

BODY:


CLARITIN'S MAKER GAINS REPRIEVE ON ITS PATENT

Drug
maker Schering-Plough Corp. yesterday said the Food and Drug Administration has approved a six-month extension on its Claritin patent because the company had tested the drug on children. Congress a few years ago agreed to give pharmaceutical makers extended patent time if they would test their medicines on children.

The extra six months means the earliest a less expensive version of the world's best-selling allergy drug can be launched is December 2002, instead of June 2002. Analysts say the extra six months can mean an extra $ 1 billion in Claritin sales.

Later this year, the FDA is expected to approve Schering-Plough's next generation Claritin medicine, which may work better than the existing drug. Schering-Plough, though, has yet to reveal what, if any, advances in treatment its new drug offers.

American Eagle profit dives

American Eagle Outfitters Inc. reported net income of $ 2.8 million for the quarter ended July 29, or 6 cents a share, down from $ 16.9 million, or 35 cents a share, in the the same period last year. The Warrendale clothier had warned earnings would take a hit because of slow sales during the spring and early summer that forced markdowns. A consensus of analysts' estimates put earnings per share at about 8 cents. Sales rose 17 percent to $ 209 million from $ 178.6 million last year. Sales in stores open at least a year fell 2.9 percent.

US Airways cuts European fares

US Airways has reduced its fares to Europe for travel from Nov. 1 to March 15. For example, round-trip fares between Pittsburgh and London's Gatwick Airport are priced as low as $ 321. Tickets must be purchased within 72 hours of making reservations, but no later than midnight Aug. 25. Restrictions -including blackout dates for travel to and from Europe -- also apply.

Steel giant cancels offering

ThyssenKrupp AG yesterday canceled plans to take its steel unit public after a slump in industry stocks made it unlikely the world's largest producer of stainless steel could raise the $ 1.4 billion intended. The German company had planned to sell one third of the unit to the public and use the cash to fund its transformation into a car parts maker. A drop in European steel shares, the worst performers in Europe this year, prompted it to abort the sale. Earlier this year the company lost an $ 8 billion battle for Mannesmann AG's car-parts unit.

Bank directors settle suit

Directors of Bank of America Corp., the top U.S. bank, yesterday agreed to pay the company $ 2.5 million to settle a shareholders' lawsuit claiming they wasted corporate assets by giving former board members $ 6 million in gifts after a 1998 merger. Charlotte, N.C.-based Bank of America, which changed its name from BankAmerica last year, was formed by the merger of the former NationsBank Corp. with Bank of America. The new company's directors subsequently mailed gifts, including $ 180,000 in cash and $ 120,000 in new stock, to 20 former directors of the two companies.

Also in business ...

Allied-SpectaGuard, formed in March with the merger of Allied Security of Pittsburgh and SpectaGuard of King of Prussia, will be known as Allied Security ... Corning Inc. announced a 3-for-1 stock split. The new shares will be issued Oct. 3 to shareholders of record as of Sept. 5 ... Dial Corp., maker of its namesake soap and Purex laundry detergent, paid $ 116.8 million to buy three businesses in the second quarter, including Procter & Gamble Co.'s Coast soap and the Zout stain remover.

LOAD-DATE: August 22, 2000




Previous Document Document 51 of 195. Next Document


FOCUS

Search Terms: patent, extension, drug
To narrow your search, please enter a word or phrase:
   
About LEXIS-NEXIS® Academic Universe Terms and Conditions Top of Page
Copyright © 2001, LEXIS-NEXIS®, a division of Reed Elsevier Inc. All Rights Reserved.